Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

SHTG Recommendation

  • Home
  • Our Advice
  • Tumour profiling tests to guide chemotherapy decisions in early breast cancer

 

 

Technology Assessment

Speciality

Output Type

Expected

Technology Assessment

Tumour profiling tests to guide chemotherapy decisions in early breast cancer

Speciality

Cancer

Output Type

SHTG Recommendation

Expected

31 July 2023

What were we asked to look at

The Scottish Health Technologies Group (SHTG) was asked to evaluate the clinical effectiveness, cost effectiveness, safety and patient experience of tumour profiling tests for guiding chemotherapy decisions for people with early stage breast cancer.  

Why is it important

Breast cancer is the most common cancer in women in Scotland accounting for 28.0% of all cancers diagnosed. There were 4,297 new cases of breast cancer diagnosed in 2020 in women in Scotland and incidence is increasing over time.1

Breast cancer is more common in affluent areas, but for women diagnosed with breast cancer survival is lower in more deprived areas. Breast cancer incidence and mortality is higher in the UK and other western countries than in the rest of the world.1

People with early and locally advanced breast cancer may need further treatment (adjuvant treatment) after they have surgery. Some people with invasive breast cancer will not need adjuvant chemotherapy. Tumour profiling tests offer a way to guide chemotherapy decisions. 

Quality performance indicators for breast cancer (published in August 2019) includes a new performance indicator for genomic tumour-profiling.2

1. https://www.scotpho.org.uk/health-wellbeing-and-disease/cancer-breast/key-points/

2. https://www.healthcareimprovementscotland.org/our_work/cancer_care_improvement/cancer_qpis/quality_performance_indicators.aspx 

Referred by  

The Scottish Cancer Network (hosted by NHS National Services Scotland)

Project Status  

In progress 

Publication Status

Draft in development
Download icon
Download Scope
pdf (536 KB)
Form icon

Register Interest


Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 18 January 2023

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?